-
Signature
-
/s/ Jacquelyn Sumer, Attorney-in-Fact
-
Issuer symbol
-
CGEM
-
Transactions as of
-
12 Dec 2025
-
Net transactions value
-
-$38,433
-
Form type
-
4
-
Filing time
-
16 Dec 2025, 17:00:13 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Michaelson Jennifer |
Chief Scientific Officer |
C/O CULLINAN THERAPEUTICS, INC., ONE MAIN STREET, SUITE 1350, CAMBRIDGE |
/s/ Jacquelyn Sumer, Attorney-in-Fact |
16 Dec 2025 |
0001838061 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
CGEM |
Common Stock |
Sale |
$26,592 |
-2,148 |
-1.5% |
$12.38 |
137,873 |
12 Dec 2025 |
Direct |
F1, F2 |
| transaction |
CGEM |
Common Stock |
Sale |
$11,840 |
-995 |
-0.72% |
$11.90 |
136,878 |
15 Dec 2025 |
Direct |
F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: